APO Research
Talk to an analyst

APO RESEARCH · REPORT

Intravenous Antibodies

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Intravenous Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026194 pages

Choose your research edition.

Industry ResearchIntravenous Antibodies Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Intravenous Antibodies Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Intravenous Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Intravenous Antibodies Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Intravenous Antibodies Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Intravenous Antibodies market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Intravenous Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Intravenous Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Intravenous Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Intravenous Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Intravenous Antibodies include Baxter, Sichuan Yuanda Shuyang, Shanghai RAAS, Octapharma, LFB Group, Kedrion, Hualan Bio, Grifols and CSL, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Intravenous Antibodies market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Intravenous Antibodies and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Intravenous Antibodies sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Intravenous Antibodies market size, projected growth trends, production technologies, key applications, and end-use industries.

Intravenous Antibodies Segment by Company

Baxter

Sichuan Yuanda Shuyang

Shanghai RAAS

Octapharma

LFB Group

Kedrion

Hualan Bio

Grifols

CSL

CNBG

CBPO

BPL

Biotest

Intravenous Antibodies Segment by Type

IgA

IgD

IgE

IgG

IgM

Intravenous Antibodies Segment by Application

Hospitals

Clinics

Others

Intravenous Antibodies Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Intravenous Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Intravenous Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Intravenous Antibodies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Intravenous Antibodies market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Intravenous Antibodies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Intravenous Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Intravenous Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Intravenous Antibodies Industry Trends Table 2. Intravenous Antibodies Industry Drivers Table 3. Intravenous Antibodies Industry Opportunities and Challenges Table 4. Intravenous Antibodies Industry Restraints Table 5. Global Intravenous Antibodies Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Intravenous Antibodies Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Intravenous Antibodies Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Intravenous Antibodies Sales Market Share by Manufacturers Table 9. Global Intravenous Antibodies Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Intravenous Antibodies Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Intravenous Antibodies Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Intravenous Antibodies Manufacturers, Product Type & Application Table 13. Global Intravenous Antibodies Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Intravenous Antibodies by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of IgA Table 17. Major Manufacturers of IgD Table 18. Major Manufacturers of IgE Table 19. Major Manufacturers of IgG Table 20. Major Manufacturers of IgM Table 21. Global Intravenous Antibodies Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Intravenous Antibodies Sales by Type (2021-2026) & (K Units) Table 23. Global Intravenous Antibodies Sales by Type (2027-2032) & (K Units) Table 24. Global Intravenous Antibodies Sales Market Share by Type (2021-2026) Table 25. Global Intravenous Antibodies Sales Market Share by Type (2027-2032) Table 26. Global Intravenous Antibodies Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Intravenous Antibodies Revenue by Type (2021-2026) & (K Units) Table 28. Global Intravenous Antibodies Revenue by Type (2027-2032) & (K Units) Table 29. Global Intravenous Antibodies Revenue Market Share by Type (2021-2026) Table 30. Global Intravenous Antibodies Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospitals Table 32. Major Manufacturers of Clinics Table 33. Major Manufacturers of Others Table 34. Global Intravenous Antibodies Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Intravenous Antibodies Sales by Application (2021-2026) & (K Units) Table 36. Global Intravenous Antibodies Sales by Application (2027-2032) & (K Units) Table 37. Global Intravenous Antibodies Sales Market Share by Application (2021-2026) Table 38. Global Intravenous Antibodies Sales Market Share by Application (2027-2032) Table 39. Global Intravenous Antibodies Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Intravenous Antibodies Revenue by Application (2021-2026) & (K Units) Table 41. Global Intravenous Antibodies Revenue by Application (2027-2032) & (K Units) Table 42. Global Intravenous Antibodies Revenue Market Share by Application (2021-2026) Table 43. Global Intravenous Antibodies Revenue Market Share by Application (2027-2032) Table 44. Global Intravenous Antibodies Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Intravenous Antibodies Sales by Region (2021-2026) & (K Units) Table 46. Global Intravenous Antibodies Sales Market Share by Region (2021-2026) Table 47. Global Intravenous Antibodies Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Intravenous Antibodies Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Intravenous Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Intravenous Antibodies Sales by Country (2021-2026) & (K Units) Table 51. North America Intravenous Antibodies Sales by Country (2027-2032) & (K Units) Table 52. Europe Intravenous Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Intravenous Antibodies Sales by Country (2021-2026) & (K Units) Table 54. Europe Intravenous Antibodies Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Intravenous Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Intravenous Antibodies Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Intravenous Antibodies Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Intravenous Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Intravenous Antibodies Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Intravenous Antibodies Sales by Country (2027-2032) & (K Units) Table 61. Global Intravenous Antibodies Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Intravenous Antibodies Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Intravenous Antibodies Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Intravenous Antibodies Revenue Market Share by Region (2021-2026) Table 65. Global Intravenous Antibodies Revenue Market Share by Region (2027-2032) Table 66. Baxter Company Information Table 67. Baxter Business Overview Table 68. Baxter Intravenous Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Baxter Intravenous Antibodies Product Portfolio Table 70. Baxter Recent Development Table 71. Sichuan Yuanda Shuyang Company Information Table 72. Sichuan Yuanda Shuyang Business Overview Table 73. Sichuan Yuanda Shuyang Intravenous Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Sichuan Yuanda Shuyang Intravenous Antibodies Product Portfolio Table 75. Sichuan Yuanda Shuyang Recent Development Table 76. Shanghai RAAS Company Information Table 77. Shanghai RAAS Business Overview Table 78. Shanghai RAAS Intravenous Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Shanghai RAAS Intravenous Antibodies Product Portfolio Table 80. Shanghai RAAS Recent Development Table 81. Octapharma Company Information Table 82. Octapharma Business Overview Table 83. Octapharma Intravenous Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Octapharma Intravenous Antibodies Product Portfolio Table 85. Octapharma Recent Development Table 86. LFB Group Company Information Table 87. LFB Group Business Overview Table 88. LFB Group Intravenous Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. LFB Group Intravenous Antibodies Product Portfolio Table 90. LFB Group Recent Development Table 91. Kedrion Company Information Table 92. Kedrion Business Overview Table 93. Kedrion Intravenous Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Kedrion Intravenous Antibodies Product Portfolio Table 95. Kedrion Recent Development Table 96. Hualan Bio Company Information Table 97. Hualan Bio Business Overview Table 98. Hualan Bio Intravenous Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Hualan Bio Intravenous Antibodies Product Portfolio Table 100. Hualan Bio Recent Development Table 101. Grifols Company Information Table 102. Grifols Business Overview Table 103. Grifols Intravenous Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Grifols Intravenous Antibodies Product Portfolio Table 105. Grifols Recent Development Table 106. CSL Company Information Table 107. CSL Business Overview Table 108. CSL Intravenous Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. CSL Intravenous Antibodies Product Portfolio Table 110. CSL Recent Development Table 111. CNBG Company Information Table 112. CNBG Business Overview Table 113. CNBG Intravenous Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. CNBG Intravenous Antibodies Product Portfolio Table 115. CNBG Recent Development Table 116. CBPO Company Information Table 117. CBPO Business Overview Table 118. CBPO Intravenous Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. CBPO Intravenous Antibodies Product Portfolio Table 120. CBPO Recent Development Table 121. BPL Company Information Table 122. BPL Business Overview Table 123. BPL Intravenous Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. BPL Intravenous Antibodies Product Portfolio Table 125. BPL Recent Development Table 126. Biotest Company Information Table 127. Biotest Business Overview Table 128. Biotest Intravenous Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Biotest Intravenous Antibodies Product Portfolio Table 130. Biotest Recent Development Table 131. Key Raw Materials Table 132. Raw Materials Key Suppliers Table 133. Intravenous Antibodies Distributors List Table 134. Intravenous Antibodies Customers List Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Intravenous Antibodies Product Image Figure 2. Global Intravenous Antibodies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Intravenous Antibodies Market Size (2021-2032) & (US$ Million) Figure 4. Global Intravenous Antibodies Sales (2021-2032) & (K Units) Figure 5. Global Intravenous Antibodies Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Intravenous Antibodies Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. IgA Image Figure 9. IgD Image Figure 10. IgE Image Figure 11. IgG Image Figure 12. IgM Image Figure 13. Global Intravenous Antibodies Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Intravenous Antibodies Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Intravenous Antibodies Sales Market Share by Type (2021-2032) Figure 16. Global Intravenous Antibodies Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Intravenous Antibodies Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Intravenous Antibodies Revenue Market Share by Type (2021-2032) Figure 19. Hospitals Image Figure 20. Clinics Image Figure 21. Others Image Figure 22. Global Intravenous Antibodies Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Intravenous Antibodies Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Intravenous Antibodies Sales Market Share by Application (2021-2032) Figure 25. Global Intravenous Antibodies Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Intravenous Antibodies Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Intravenous Antibodies Revenue Market Share by Application (2021-2032) Figure 28. North America Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Intravenous Antibodies Sales Market Share by Country (2021-2032) Figure 30. U.S. Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Intravenous Antibodies Sales Market Share by Country (2021-2032) Figure 35. Germany Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Intravenous Antibodies Sales Market Share by Country (2021-2032) Figure 42. China Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Intravenous Antibodies Sales Market Share by Country (2021-2032) Figure 50. Brazil Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Intravenous Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Intravenous Antibodies Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Intravenous Antibodies Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Intravenous Antibodies Revenue (2021-2032) & (US$ Million) Figure 61. North America Intravenous Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Intravenous Antibodies Revenue (2021-2032) & (US$ Million) Figure 63. Europe Intravenous Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Intravenous Antibodies Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Intravenous Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Intravenous Antibodies Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Intravenous Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Intravenous Antibodies Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Intravenous Antibodies Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • IgA
  • IgD
  • IgE
  • IgG
  • IgM
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Baxter
  • Sichuan Yuanda Shuyang
  • Shanghai RAAS
  • Octapharma
  • LFB Group
  • Kedrion
  • Hualan Bio
  • Grifols
  • CSL
  • CNBG
  • CBPO
  • BPL
  • Biotest

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Intravenous Antibodies Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Intravenous Antibodies Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Intravenous Antibodies Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Intravenous Antibodies Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Intravenous Antibodies Market Dynamics
  1. 2.1 Intravenous Antibodies Industry Trends
  2. 2.2 Intravenous Antibodies Industry Drivers
  3. 2.3 Intravenous Antibodies Industry Opportunities and Challenges
  4. 2.4 Intravenous Antibodies Industry Restraints
3 Intravenous Antibodies Market by Manufacturers
  1. 3.1 Global Intravenous Antibodies Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Intravenous Antibodies Sales by Manufacturers (2021-2026)
  3. 3.3 Global Intravenous Antibodies Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Intravenous Antibodies Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Intravenous Antibodies Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Intravenous Antibodies Manufacturers, Product Type & Application
  7. 3.7 Global Intravenous Antibodies Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Intravenous Antibodies Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Intravenous Antibodies Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Intravenous Antibodies Tier 1, Tier 2, and Tier 3
4 Intravenous Antibodies Market by Type
  1. 4.1 Intravenous Antibodies Type Introduction
  2. 4.1.1 IgA
  3. 4.1.2 IgD
  4. 4.1.3 IgE
  5. 4.1.4 IgG
  6. 4.1.5 IgM
  7. 4.2 Global Intravenous Antibodies Sales by Type
  8. 4.2.1 Global Intravenous Antibodies Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Intravenous Antibodies Sales by Type (2021-2032)
  10. 4.2.3 Global Intravenous Antibodies Sales Market Share by Type (2021-2032)
  11. 4.3 Global Intravenous Antibodies Revenue by Type
  12. 4.3.1 Global Intravenous Antibodies Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Intravenous Antibodies Revenue by Type (2021-2032)
  14. 4.3.3 Global Intravenous Antibodies Revenue Market Share by Type (2021-2032)
5 Intravenous Antibodies Market by Application
  1. 5.1 Intravenous Antibodies Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Intravenous Antibodies Sales by Application
  6. 5.2.1 Global Intravenous Antibodies Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Intravenous Antibodies Sales by Application (2021-2032)
  8. 5.2.3 Global Intravenous Antibodies Sales Market Share by Application (2021-2032)
  9. 5.3 Global Intravenous Antibodies Revenue by Application
  10. 5.3.1 Global Intravenous Antibodies Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Intravenous Antibodies Revenue by Application (2021-2032)
  12. 5.3.3 Global Intravenous Antibodies Revenue Market Share by Application (2021-2032)
6 Global Intravenous Antibodies Sales by Region
  1. 6.1 Global Intravenous Antibodies Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Intravenous Antibodies Sales by Region (2021-2032)
  3. 6.2.1 Global Intravenous Antibodies Sales by Region (2021-2026)
  4. 6.2.2 Global Intravenous Antibodies Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Intravenous Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Intravenous Antibodies Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Intravenous Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Intravenous Antibodies Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Intravenous Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Intravenous Antibodies Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Intravenous Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Intravenous Antibodies Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Intravenous Antibodies Revenue by Region
  1. 7.1 Global Intravenous Antibodies Revenue by Region
  2. 7.1.1 Global Intravenous Antibodies Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Intravenous Antibodies Revenue by Region (2021-2026)
  4. 7.1.3 Global Intravenous Antibodies Revenue by Region (2027-2032)
  5. 7.1.4 Global Intravenous Antibodies Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Intravenous Antibodies Revenue (2021-2032)
  8. 7.2.2 North America Intravenous Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Intravenous Antibodies Revenue (2021-2032)
  11. 7.3.2 Europe Intravenous Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Intravenous Antibodies Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Intravenous Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Intravenous Antibodies Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Intravenous Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Baxter
  2. 8.1.1 Baxter Company Information
  3. 8.1.2 Baxter Business Overview
  4. 8.1.3 Baxter Intravenous Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Baxter Intravenous Antibodies Product Portfolio
  6. 8.1.5 Baxter Recent Developments
  7. 8.2 Sichuan Yuanda Shuyang
  8. 8.2.1 Sichuan Yuanda Shuyang Company Information
  9. 8.2.2 Sichuan Yuanda Shuyang Business Overview
  10. 8.2.3 Sichuan Yuanda Shuyang Intravenous Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sichuan Yuanda Shuyang Intravenous Antibodies Product Portfolio
  12. 8.2.5 Sichuan Yuanda Shuyang Recent Developments
  13. 8.3 Shanghai RAAS
  14. 8.3.1 Shanghai RAAS Company Information
  15. 8.3.2 Shanghai RAAS Business Overview
  16. 8.3.3 Shanghai RAAS Intravenous Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai RAAS Intravenous Antibodies Product Portfolio
  18. 8.3.5 Shanghai RAAS Recent Developments
  19. 8.4 Octapharma
  20. 8.4.1 Octapharma Company Information
  21. 8.4.2 Octapharma Business Overview
  22. 8.4.3 Octapharma Intravenous Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Octapharma Intravenous Antibodies Product Portfolio
  24. 8.4.5 Octapharma Recent Developments
  25. 8.5 LFB Group
  26. 8.5.1 LFB Group Company Information
  27. 8.5.2 LFB Group Business Overview
  28. 8.5.3 LFB Group Intravenous Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 LFB Group Intravenous Antibodies Product Portfolio
  30. 8.5.5 LFB Group Recent Developments
  31. 8.6 Kedrion
  32. 8.6.1 Kedrion Company Information
  33. 8.6.2 Kedrion Business Overview
  34. 8.6.3 Kedrion Intravenous Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Kedrion Intravenous Antibodies Product Portfolio
  36. 8.6.5 Kedrion Recent Developments
  37. 8.7 Hualan Bio
  38. 8.7.1 Hualan Bio Company Information
  39. 8.7.2 Hualan Bio Business Overview
  40. 8.7.3 Hualan Bio Intravenous Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Hualan Bio Intravenous Antibodies Product Portfolio
  42. 8.7.5 Hualan Bio Recent Developments
  43. 8.8 Grifols
  44. 8.8.1 Grifols Company Information
  45. 8.8.2 Grifols Business Overview
  46. 8.8.3 Grifols Intravenous Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Grifols Intravenous Antibodies Product Portfolio
  48. 8.8.5 Grifols Recent Developments
  49. 8.9 CSL
  50. 8.9.1 CSL Company Information
  51. 8.9.2 CSL Business Overview
  52. 8.9.3 CSL Intravenous Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 CSL Intravenous Antibodies Product Portfolio
  54. 8.9.5 CSL Recent Developments
  55. 8.10 CNBG
  56. 8.10.1 CNBG Company Information
  57. 8.10.2 CNBG Business Overview
  58. 8.10.3 CNBG Intravenous Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 CNBG Intravenous Antibodies Product Portfolio
  60. 8.10.5 CNBG Recent Developments
  61. 8.11 CBPO
  62. 8.11.1 CBPO Company Information
  63. 8.11.2 CBPO Business Overview
  64. 8.11.3 CBPO Intravenous Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 CBPO Intravenous Antibodies Product Portfolio
  66. 8.11.5 CBPO Recent Developments
  67. 8.12 BPL
  68. 8.12.1 BPL Company Information
  69. 8.12.2 BPL Business Overview
  70. 8.12.3 BPL Intravenous Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 BPL Intravenous Antibodies Product Portfolio
  72. 8.12.5 BPL Recent Developments
  73. 8.13 Biotest
  74. 8.13.1 Biotest Company Information
  75. 8.13.2 Biotest Business Overview
  76. 8.13.3 Biotest Intravenous Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Biotest Intravenous Antibodies Product Portfolio
  78. 8.13.5 Biotest Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Intravenous Antibodies Value Chain Analysis
  2. 9.1.1 Intravenous Antibodies Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Intravenous Antibodies Production Mode & Process
  6. 9.2 Intravenous Antibodies Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Intravenous Antibodies Distributors
  9. 9.2.3 Intravenous Antibodies Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst